Please ensure Javascript is enabled for purposes of website accessibility

Why Esperion Therapeutics Plummeted Nearly 22% Today

By Eric Volkman - May 5, 2021 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was all about the earnings.

What happened

Esperion Therapeutics (ESPR 2.55%) widely missed on its first-quarter results. Those figures were published after market hours Tuesday, so the Wednesday fallout was ugly, with the company's stock closing 21.8% lower.

So what

In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000). On the bottom line, the biotech posted a loss of $90.9 million -- $3.50 per share -- compared to the year-ago deficit of $78.2 million. The company's tally of cash, cash equivalents, and liquid securities fell to $217.9 million from $305 million at the end of the preceding quarter.

A piggy bank with a stethoscope wrapped around it.

Image source: Getty Images.

While at first glance, that top-line growth was robust and encouraging, the average analyst estimate was far higher, at slightly more than $22 million. Esperion also missed significantly on the bottom line, as those prognosticators were collectively estimating only a $2.52 per share loss.

The company proffered selected guidance for full-year 2021. It believes it will book total operating expenses of $320 million to $340 million for the year. It did not provide revenue or profitability forecasts.

Now what

While a biotech's quarterly results can land far from estimates due to the frequent feast-or-famine nature of the business, Esperion's Q1 whiffs were significant. Also, the company's research and development expenses fell during the quarter, while its selling, general, and administrative expenses rose nearly 50% -- not an encouraging dynamic in a research-dependent sector like biotech.

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Esperion Therapeutics Stock Quote
Esperion Therapeutics
ESPR
$6.84 (2.55%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.